Postexposure prophylaxis for influenza in pediatric wards oseltamivir or zanamivir after rapid antigen detection

Pediatric Infectious Disease Journal

Volumn 31, Issue 11, 2012, Pages 1119-1123

  Shinjoh, Masayoshi ^a,b   Takano, Yaoko ^b   Takahashi, Takao ^a,b   Hasegawa, Naoki ^b   Iwata, Satoshi ^b   Sugaya, Norio ^c  

^a KEIO UNIVERSITY   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Keiyu Hospital   (Japan)

Author keywords

influenza virus; oseltamivir; pediatric; postexposure prophylaxis; zanamivir

Indexed keywords

OSELTAMIVIR; ZANAMIVIR;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; DRUG SAFETY; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; IMMUNOASSAY; INFANT; INFLUENZA A; INFLUENZA B; MEDICAL STAFF; PEDIATRIC WARD; POST EXPOSURE PROPHYLAXIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RAPID ANTIGEN DETECTION; SCHOOL CHILD; SECONDARY INFECTION;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; HEALTH PERSONNEL; HUMANS; INFANT; INFLUENZA, HUMAN; INPATIENTS; ORTHOMYXOVIRIDAE; OSELTAMIVIR; YOUNG ADULT; ZANAMIVIR;

EID: 84867868477     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318260265a     Document Type: Article

References (39)

1. Glezen WP. Influenza viruses. In: Feigin RD, Cherry JD, Demmler-Harrison GJ, et al, eds Textbook of Pediatric Infectious Diseases, 6th ed. Philadelphia: Saunders Elsevier 2009; 2395-2413.
2. Shinjoh M, Bamba M, Jozaki K, et al. Influenza A-associated encephalopathy with bilateral thalamic necrosis in Japan. Clin Infect Dis. 2000;31:611- 613. (Pubitemid 32289602)
3. Sugaya N. Influenza-associated encephalopathy in Japan. Semin Pediatr Infect Dis. 2002;13:79-84. (Pubitemid 34492547)
4. Klontz KC, Hynes NA, Gunn RA, et al. An outbreak of influenza A/Taiwan/1/86 (H1N1) infections at a naval base and its association with airplane travel. Am J Epidemiol. 1989;129:341-348. (Pubitemid 19046999)
5. Fiore AE, Fry A, Shay D, et al. Centers for Disease Control and Prevention (CDC). Antiviral agents for the treatment and chemoprophylaxis of influenza-recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60:1-24.
6. Coburn BJ, Wagner BG, Blower S. Modeling influenza epidemics and pandemics: insights into the future of swine flu (H1N1). BMC Med. 2009;7:30.
7. Brown ST, Tai JH, Bailey RR, et al. Would school closure for the 2009 H1N1 influenza epidemic have been worth the cost? A computational simulation of Pennsylvania. BMC Public Health. 2011;11:353.
8. Baz M, Abed Y, McDonald J, et al. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis. 2006;43:1555-1561. (Pubitemid 44901897)
9. Sugaya N, Kusumoto N, Suzuki Y, et al. Large sequential outbreaks caused by influenza A (H3N2) and B viruses in an institution for the mentally handicapped. J Med Virol. 1996;50:120-125. (Pubitemid 26379297)
10. Maltezou HC, Drancourt M. Nosocomial influenza in children. J Hosp Infect. 2003;55:83-91. (Pubitemid 38001959)
11. O'Donoghue JM, Ray CG, Terry DW Jr, et al. Prevention of nosocomial influenza infection with Amantadine. Am J Epidemiol. 1973;97:276-282.
12. Jackson RJ, Cooper KL, Tappenden P, et al. Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. J Infect. 2011;62:14-25.
13. Gaillat J, Dennetière G, Raffin-Bru E, et al. Summer influenza outbreak in a home for the elderly: application of preventive measures. J Hosp Infect. 2008;70:272-277.
14. Vu D, Peck AJ, Nichols WG, et al. Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study. Clin Infect Dis. 2007;45:187-193. (Pubitemid 47041009)
15. Gravenstein S, Drinka P, Osterweil D, et al. Inhaled zanamivir versus rimantadine for the control of influenza in a highly vaccinated long-term care population. J Am Med Dir Assoc. 2005;6:359-366. (Pubitemid 41755354)
16. Ambrozaitis A, Gravenstein S, van Essen GA, et al. Inhaled zanamivir versus placebo for the prevention of influenza outbreaks in an unvaccinated long-term care population. J Am Med Dir Assoc. 2005;6:367-374. (Pubitemid 41755355)
17. Buchbinder N, Dumesnil C, Pinquier D, et al. Pandemic A/H1N1/2009 influenza in a paediatric haematology and oncology unit: successful management of a sudden outbreak. J Hosp Infect. 2011;79:155-160.
18. Sugaya N, Mitamura K, Yamazaki M, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis. 2007;44:197-202. (Pubitemid 46079980)
19. De Witte E, Goossens H, Ieven M. Evaluation of the ESPLINE® Influenza A & B-N assay for the detection of influenza A and B in nasopharyngeal aspirates. Eur J Clin Microbiol Infect Dis. 2012;31:761-766.
20. Sakai-Tagawa Y, Ozawa M, Tamura D, et al. Sensitivity of influenza rapid diagnostic tests to H5N1 and 2009 pandemic H1N1 viruses. J Clin Microbiol. 2010;48:2872-2877.
21. Watanabe M, Nakagawa N, Ito M, et al. Sensitivity of rapid immunoassay for influenza A and B in the early phase of the disease. Pediatr Int. 2009;51:211-215.
22. Mitamura K, Yamazaki M, Ichikawa M, et al. [Evaluation of an immunochromatography test using enzyme immunoassay for rapid detection of influenza A and B viruses]. Kansenshogaku Zasshi. 2004;78:597-603.
23. Shinjoh M, Sato S, Sugaya N, et al. [Effect of post-exposure prophylaxis with oseltamivir for those in contacts with influenza patients in pediatric wards]. Kansenshogaku Zasshi. 2004;78:262-269.
24. Shinjoh M, Takahashi T. Varicella zoster exposure on paediatric wards between 2000 and 2007: safe and effective post-exposure prophylaxis with oral aciclovir. J Hosp Infect. 2009;72:163-168.
25. Terada K, Kawai Y, Monju A, et al. Adolescent jump case in Japan associated with influenza but not oseltamivir. Pediatr Infect Dis J. 2008;27:88-89.
26. Fiore AE, Uyeki TM, Broder K, et al. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):1-62.
27. Welliver R, Monto AS, Carewicz O, et al. Oseltamivir Post Exposure Prophylaxis Investigator Group. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001;285:748-754. (Pubitemid 32167233)
28. Hayden FG, Belshe R, Villanueva C, et al. Management of influenza in households: a prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis. J Infect Dis. 2004;189:440-449. (Pubitemid 38210580)
29. Hayden FG, Gubareva LV, Monto AS, et al. Zanamivir Family Study Group. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med. 2000;343:1282-1289.
30. Monto AS, Pichichero ME, Blanckenberg SJ, et al. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis. 2002;186:1582-1588. (Pubitemid 35379634)
31. Siegel JD, Rhinehart E, Jackson M, et al. Health Care Infection Control Practices Advisory Committee. 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. Am J Infect Control. 2007;35(10 suppl 2):S65-164.
32. Sugaya N, Nerome K, Ishida M, et al. Impact of influenza virus infection as a cause of pediatric hospitalization. J Infect Dis. 1992;165:373-375.
33. Kawai S, Nanri S, Ban E, et al. Influenza vaccination of schoolchildren and influenza outbreaks in a school. Clin Infect Dis. 2011;53:130-136.
34. Sugaya N, Nerome K, Ishida M, et al. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B. JAMA. 1994;272:1122-1126. (Pubitemid 24299346)
35. Hatakeyama S, Sugaya N, Ito M, et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA. 2007;297:1435- 1442. (Pubitemid 46556469)
36. Oo C, Hill G, Dorr A, et al. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years. Eur J Clin Pharmacol. 2003;59:411- 415. (Pubitemid 37214948)
37. Cass LM, Brown J, Pickford M, et al. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet. 1999;36 (suppl 1):21-31. (Pubitemid 29322454)
38. Chen LF, Dailey NJ, Rao AK, et al. Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients-North Carolina, 2009. J Infect Dis. 2011; 203:838-846.
39. Moore C, Galiano M, Lackenby A, et al. Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit. J Infect Dis. 2011;203:18-24.